Oncternal Therapeutics, Inc. (ONCT)
Dec 3, 2024 - ONCT trading suspended
0.5266
-0.1670 (-24.12%)
Inactive · Last trade price on Dec 2, 2024

Oncternal Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingSep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Revenue
2.160.791.494.323.382.43
Revenue Growth
227.92%-47.32%-65.47%27.85%39.17%-3.81%
Gross Profit
-22.93-28.97-31.49-19.77-9.17-7.73
Operating Income
-34.86-41.71-44.95-31.37-17.54-15.02
Net Income
-34.58-39.48-44.17-31.33-17.23-34.19
Earnings Per Share
-11.69-13.43-16.79-12.71-16.97-66.20
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingSep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Cash & Investments
14.5834.2663.7290.77116.7420.05
Total Debt
0.190.320.090.080.040.19
Net Cash (Debt)
14.3933.9463.6490.69116.719.86
Net Cash Growth
-64.00%-46.67%-29.83%-22.29%487.57%-3.80%
Net Cash Per Share
4.8611.5424.2036.78114.9438.46

Cash Flow & CapEx

Fiscal YearTTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingSep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Operating Cash Flow
-26.63-32.16-36.7-26.59-17.5-16.75
Free Cash Flow
-26.63-32.16-36.7-26.59-17.5-16.75
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingSep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Gross Margin
-----271.67%-
Operating Margin
-1613.10%-5313.89%-3016.58%-726.91%-519.76%-619.38%
Pretax Margin
-1599.95%-5029.17%-2964.43%-726.14%-510.37%-1409.81%
Profit Margin
-1599.95%-5029.17%-2964.43%-726.14%-510.37%-1409.81%
FCF Margin
-1232.39%-4097.32%-2463.36%-616.20%-518.37%-690.56%

Valuation

Fiscal YearCurrentFY 2023FY 2022FY 2021FY 2020FY 2019
Period EndingAug '26 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
PS Ratio
0.7240.2837.8126.0070.8025.06